REGENERON PHARMACEUTICALS, INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
REGENERON PHARMACEUTICALS, INC. (REGN) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $576.70 million as of 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-02-04
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $576.70M.
- 2024-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $591.20M.
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $605.70M.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $620.30M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2025-12-31 | $576.70M 10-K · filed 2026-02-04 |
| 2024-12-31 | $591.20M 10-K · filed 2026-02-04 |
| 2023-12-31 | $605.70M 10-K · filed 2025-02-05 |
| 2022-12-31 | $620.30M 10-K · filed 2024-02-05 |
| 2021-12-31 | $631.30M 10-K · filed 2023-02-06 |
| 2020-12-31 | $645.70M 10-K · filed 2022-02-07 |
| 2019-12-31 | $660.10M 10-K · filed 2021-02-08 |
| 2019-09-30 | $663.70M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $667.30M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $670.90M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |